# Yunfei Cao

> Yunfei 'Richard' Cao is the co-founder and CEO of Angio8 (通甪科技), a Shenzhen-based startup building a next-generation surgical robot for minimally invasive vascular interventional surgery. A Stony Brook biomedical engineer who cut his teeth inside the Boston medical-device machine at Vention Medical, SunMed and China Med Device, Cao now runs a cross-Pacific company - engineering brains in Boston, manufacturing and clinical work in Shenzhen - aimed at letting doctors steer catheters and guidewires by robot instead of by hand.

- **Role:** Co-Founder & CEO at Angio8 (通甪科技)
- **Organizations:** Angio8 (通甪科技), Boston Innovation Technology, China Med Device, SunMed, Vention Medical
- **Nationality:** Chinese
- **Education:** Bachelor of Engineering, Biomedical Engineering, State University of New York at Stony Brook
- **Known for:** Co-founded and leads Angio8, a company developing a next-generation vascular interventional surgical robot, Built a cross-Pacific operation with an R&D center in Boston and headquarters/clinical operations in Shenzhen, Raised institutional venture funding (Series A and beyond) from Chinese medtech-focused investors

## Career timeline

- **2008-2013** — Studies Biomedical Engineering at Stony Brook University (SUNY)
- **2013-2021** — Works across the Boston-area medical device industry, including roles connected to Vention Medical, SunMed, China Med Device and Boston Innovation Technology
- **2021** — Co-founds Angio8 (通甪科技) in Shenzhen's Nanshan district in December, targeting vascular interventional surgical robotics
- **2023** — Angio8 closes a Series A round (tens of millions RMB) with Oriental Fortune Capital, Kangyu Capital and Ruiqian Capital
- **2025** — Angio8 continues fundraising with a further round reported around September, backed again by Ruiqian Capital

## Achievements

- Co-founded and leads Angio8, a company developing a next-generation vascular interventional surgical robot
- Built a cross-Pacific operation with an R&D center in Boston and headquarters/clinical operations in Shenzhen
- Raised institutional venture funding (Series A and beyond) from Chinese medtech-focused investors
- Assembled a core team combining medical-device industry veterans with surgical-robotics technologists

## Latest updates

- **2025-09** — Angio8 reported an additional funding round, continuing to back product development and clinical trials for its vascular interventional surgical robot.

## Links

- Website: https://angio8.com
- LinkedIn: http://www.linkedin.com/in/yunfei-richard-cao-aa893860

---

Profile page: https://yespress.io/yunfei-cao
Published by YesPress — https://yespress.io
Last updated: 2026-07-07